THIS SITE IS FOR US AUDIENCES ONLY.

Important Safety Information

It is not known if Xofigo is safe and effective in women. Xofigo can harm unborn babies when given to a pregnant woman. Men should use condoms and make sure female partners who may become pregnant use birth control (contraception) during treatment and for 6 months after completing treatment with Xofigo.

Continue reading below


EVERYONE'S PROSTATE CANCER STORY IS DIFFERENT—BUT TREATMENT GOALS REMAIN THE SAME

There are thousands of men, just like you, who are fighting prostate cancer that has spread to the bones. One of the reasons it may have spread is because your cancer is no longer responding to therapies aimed at lowering testosterone. The medical term for this condition is metastatic castration-resistant prostate cancerX metastatic castration-resistant prostate cancer
The medical term for when prostate cancer has spread to bone and the cancer is no longer responding to therapies aimed at lowering testosterone.
(mCRPCX mCRPC
The medical term for when prostate cancer has spread to bone and the cancer is no longer responding to therapies aimed at lowering testosterone.
).

When prostate cancer spreads to your bones, a treatment change may be necessary.

For 9 out of 10 men with mCRPC Prostate cancer spreads to the bones

It is important to know that even if the cancer has spread to your bones and you may no longer have a prostate, it is still considered prostate cancer, not bone cancer.

Your doctor may also refer to advanced prostate cancerX advanced prostate cancer
Cancer that has spread outside the prostate to other parts of the body.
 as “metastatic” or “late-stage” disease. It may also be referred to as “mCRPCX mCRPC
The medical term for when prostate cancer has spread to bone and the cancer is no longer responding to therapies aimed at lowering testosterone.
.”

How you and your doctor can monitor your disease

ALP TEST

If your doctor suspects prostate cancer has spread to your bones, tests such as a bone scanX bone scan
This test of the entire skeleton can show if prostate cancer has spread to the bones.
, checking ALPX ALP
A substance that may be released into the bloodstream when bones break down.
 levels, or a PSA testX PSA test
A test that screens for prostate cancer, but is also an important tool for men with the disease to determine how their cancer is reacting to treatment.
 should be considered. ALP is a substance that may be released into the bloodstream when bones break down. High levels of ALP give your doctor a better idea if your disease has spread to bone.

PSA TEST

PSAX PSA
A substance that is released into the bloodstream and is usually at high levels in men with prostate cancer.
tests screen for prostate cancer but are also an important tool for men with the disease to determine how their cancer is reacting to treatment. Changes in your PSA levels may be a sign that your disease is advancing. In advanced prostate cancerX advanced prostate cancer
Cancer that has spread outside the prostate to other parts of the body.
, PSA tests alone should not be used to determine long-term outcomes, like living longer.

BE OPEN AND HONEST WITH YOUR DOCTORS. THIS WILL HELP THEM FIGURE OUT IF A TREATMENT CHANGE OR AN ADDITIONAL THERAPY IS THE RIGHT APPROACH FOR YOU.

 

Indication

Xofigo® (radium Ra 223 dichloride) injection is used to treat prostate cancer that no longer responds to hormonal or surgical treatment that lowers testosterone. It is for men whose prostate cancer has spread to the bone with symptoms but not to other parts of the body.

Important Safety Information

It is not known if Xofigo is safe and effective in women. Xofigo can harm unborn babies when given to a pregnant woman. Men should use condoms and make sure female partners who may become pregnant use birth control (contraception) during treatment and for 6 months after completing treatment with Xofigo.

Before taking Xofigo, tell your healthcare provider if you:

  • have bone marrow problems. Xofigo can cause your blood cells counts to go down, including red blood cells, white blood cells, and/or platelets. In a clinical trial, some patients had to permanently discontinue therapy because of bone marrow problems. In addition, there were some deaths and blood transfusions that occurred due to severe bone marrow problems. Your healthcare provider will do blood tests before and during treatment with Xofigo
  • are receiving any chemotherapy or another extensive radiation therapy
  • are taking Zytiga® (also known as abiraterone) with prednisone/prednisolone, as this may increase the risk of bone fractures (breaks) and death
  • have any other medical conditions

While you are on Xofigo:

  • make sure you keep your blood cell count monitoring appointments and tell your healthcare provider about any symptoms or signs of low blood cell counts. Report symptoms or signs of shortness of breath, tiredness, bleeding (such as bruising), or infection (such as fever)
  • stay well hydrated and report any signs of dehydration (such as dry mouth and increased thirst), or urinary or kidney problems (such as burning when urinating)
  • there are no restrictions regarding personal contact (visual or physical proximity) with other people after receiving Xofigo
  • people who are handling fluids such as urine, feces, or vomit of a man taking Xofigo should wear gloves and wash their hands as precaution
  • follow good hygiene practices in order to minimize radiation exposure from spills of bodily fluids to household members and caregivers for a period of one week after each injection

The most common side effects of Xofigo include:

  • nausea
  • diarrhea
  • vomiting
  • swelling of the arms or legs (peripheral edema)
  • low blood cell counts

Tell your healthcare provider if you have any side effects that bother you or do not go away.

For important risk and use information about Xofigo, please see the Full Prescribing Information.

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.